These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 15917881

  • 1. The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers.
    Mancini GB.
    Can J Cardiol; 2005 May 01; 21(6):519-23. PubMed ID: 15917881
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
    Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM.
    J Am Coll Cardiol; 2006 Jun 20; 47(12):2554-60. PubMed ID: 16781387
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 20; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U, Deedwania PC.
    Cardiol Clin; 2008 Nov 20; 26(4):507-26. PubMed ID: 18929228
    [Abstract] [Full Text] [Related]

  • 7. [Chronic obstructive pulmonary disease and cardiovascular system].
    Gürgün A, Gürgün C.
    Tuberk Toraks; 2008 Nov 20; 56(4):464-71. PubMed ID: 19123087
    [Abstract] [Full Text] [Related]

  • 8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 20; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
    Chrysant SG.
    Clin Ther; 2008 Jul 20; 30 Pt 2():2181-90. PubMed ID: 19281913
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M.
    Am J Cardiol; 2007 Aug 06; 100(3A):38J-44J. PubMed ID: 17666197
    [Abstract] [Full Text] [Related]

  • 11. Can beta-blockers be used for people with COPD?
    Drug Ther Bull; 2011 Jan 06; 49(1):2-5. PubMed ID: 21220252
    [Abstract] [Full Text] [Related]

  • 12. What is the role of angiotensin-receptor blockade in cardiovascular protection?
    Cohn JN.
    Am Heart J; 2006 Nov 06; 152(5):859.e1-8. PubMed ID: 17070145
    [Abstract] [Full Text] [Related]

  • 13. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V.
    Nephrol Ther; 2006 May 06; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [Abstract] [Full Text] [Related]

  • 14. [Chronic obstructive pulmonary disease and cardiovascular disease].
    Alonso JL.
    Arch Bronconeumol; 2010 May 06; 46 Suppl 3():18-22. PubMed ID: 20620688
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H.
    Ther Adv Cardiovasc Dis; 2009 Oct 06; 3(5):397-405. PubMed ID: 19491138
    [Abstract] [Full Text] [Related]

  • 16. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease.
    Sin DD, Man SF.
    Curr Opin Pulm Med; 2008 Mar 06; 14(2):115-21. PubMed ID: 18303420
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
    Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F.
    Blood Press; 2005 Mar 06; 14(4):196-209. PubMed ID: 16126553
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
    Dagenais NJ, Jamali F.
    Pharmacotherapy; 2005 Sep 06; 25(9):1213-29. PubMed ID: 16164395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.